Smith & Nephew plc (LON:SN) Receives GBX 1,340.11 Consensus Target Price from Analysts

Shares of Smith & Nephew plc (LON:SN) have received an average recommendation of “Hold” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is GBX 1,340.11.

SN has been the topic of several analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,350 price target on shares of Smith & Nephew in a report on Monday, June 29th. Shore Capital Group reissued a “buy” rating and set a GBX 1,000 target price on shares of Smith & Nephew in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,400 target price on shares of Smith & Nephew in a research report on Thursday, July 30th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,760 target price on shares of Smith & Nephew in a research note on Thursday, May 21st. Finally, Berenberg Bank reaffirmed a “hold” rating and issued a GBX 13 target price on shares of Smith & Nephew in a report on Friday, May 1st.

Smith & Nephew Stock Up 3.3%

LON SN opened at GBX 1,197 on Tuesday. The company has a 50-day simple moving average of GBX 1,134.89 and a 200 day simple moving average of GBX 1,194.79. The firm has a market capitalization of £13.12 billion, a PE ratio of 43.10, a PEG ratio of 0.46 and a beta of 0.69. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.